MedTrace Logo

Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition

NCT00484757 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2009-04-03

No results posted yet for this study

Summary

15 patients with narcolepsy and 15 healthy controls will be included in the study. According to a randomized, double-blind protocol they will receive intranasally at night first Orexine A and approximately two weeks later placebo or vice versa. Thereafter sleep will be recorded, the cytokine-system and neurocognition characterized.

Conditions

Interventions

DRUG

Orexine A

Sponsors & Collaborators

  • Zentrum für Integrative Psychiatrie

    lead OTHER

Principal Investigators

  • Dunja Hinze-Selch, MD · Zentrum für Integrative Psychiatrie

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484757 on ClinicalTrials.gov